| Entry |
|
|---|
| Name |
Erlotinib hydrochloride (JAN/USAN);
Tarceva (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C22H23N3O4. HCl
|
|---|
| Exact mass |
429.1455
|
|---|
| Mol weight |
429.8967
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00711): | D04023<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Non-small cell lung cancer (EGFR mutation positive) [DS: H00014] Pancreatic cancer [DS: H00019] |
|---|
| Target |
|
|---|
| Network |
| N10005 | First/second-generation tyrosine kinase inhibitor to EGFR mutation |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP1A2 [HSA: 1544]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE03 Erlotinib
D04023 Erlotinib hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Erlotinib
D04023 Erlotinib hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D04023 Erlotinib hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR* [HSA_VAR:1956v2]
D04023 Erlotinib hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04023
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04023
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04023
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04023
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04023
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D04023
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 30
1 C8x C 22.3300 -16.9400
2 N5x N 22.3300 -18.3400
3 C8y C 23.5900 -19.0400
4 C8y C 24.7800 -18.3400
5 C8y C 24.7800 -16.9400
6 N5x N 23.5900 -16.2400
7 C8x C 25.9700 -19.0400
8 C8y C 27.1600 -18.3400
9 C8y C 27.1600 -16.9400
10 C8x C 25.9700 -16.2400
11 N1b N 23.5900 -20.3700
12 C8y C 24.7800 -21.0700
13 C8x C 24.7800 -22.4700
14 C8x C 25.9700 -23.1700
15 C8y C 27.1600 -22.4700
16 C8x C 27.1600 -21.0700
17 C8x C 25.9700 -20.3700
18 C3b C 28.3753 -23.1651
19 C3a C 29.5877 -23.8651
20 O2a O 28.3724 -16.2400
21 C1b C 29.5849 -16.9400
22 C1b C 30.7973 -16.2400
23 O2a O 32.0097 -16.9400
24 C1a C 33.2222 -16.2400
25 O2a O 28.3724 -19.0400
26 C1b C 29.5849 -18.3400
27 C1b C 30.7973 -19.0400
28 O2a O 32.0097 -18.3400
29 C1a C 33.2222 -19.0400
30 X Cl 38.7100 -19.5300
BOND 31
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 2
7 4 7 2
8 7 8 1
9 8 9 2
10 9 10 1
11 5 10 2
12 3 11 1
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 12 17 1
20 15 18 1
21 18 19 3
22 9 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 23 24 1
27 8 25 1
28 25 26 1
29 26 27 1
30 27 28 1
31 28 29 1
|
|---|
